Discussion Points:

1. Strategies for Enhancing Targeted Delivery with Next-Generation LNPs

• What advances in lipid composition, particle engineering, or surface modification are most promising for cell- or tissue-specific delivery of oligonucleotide therapeutics?

2. Analytical Tools and Quality Standards for LNP Characterization

• Which cutting-edge analytical methods are enabling more robust, reproducible measurement of LNP size, encapsulation efficiency, stability, and payload integrity - and how are these impacting clinical translation?

3. Overcoming Challenges in Manufacturing and Scale-Up

• What recent solutions address the reproducibility, scalability, and regulatory compliance of LNP-based oligonucleotide therapies from lab to clinic? Where are the current bottlenecks?